1 BETA-CELL FAILURE IN DIABETES AND PRESERVATION BY ...

More documents

Recommendations

Info

1 References 1.UK Prospective Diabetes Study(UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33) 1998.Lancet 352:837-853. 2. UK Prospective Diabetes Study(UKPDS) Group.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34) 1998.Lancet 352:854-865 3. Holman RR 1998 Assessing the potential for alpha-glucosidase inhibitors in prediabetic states .Diabetes Res Clin Pract 40(Suppl) S21-25 4. Butler AE,Janson J,Bonner-Weir S,Ritzel R,Rizza RA,Butler PC 2003. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110 5.Wallace TM,Levy JC,Matthews DR 2004. Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495 6. Matthews DR 2001.Insulin resistance and β-cell function – a clinical perspective.Diabetes Obes Metab 3(Suppl 1):S28-S33. 7. UK Prospective Diabetes Study(UKPDS) Group. Overview of 6 years`therapy of type II diabetes :a progressive disease (UKPDS 16) 1995 .Diabetes 44:1249-1258 8. Östgren CJ,Lindblad U,Ranstam J,Melander A,Rastam L 2002.Glycaemic control,disease duration and β-cell function in patients with Type 2 diabetes in a Swedish community.Skaraborg Hypertension and Diabetes Project. Diabet Med 19:125-129 9 Mattthews DR,Hosker JP,Rudenski AS,Naylor BA,Teacher DF,Turner RC 1985 Homeostasis model assessment :insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man.Diabetologia 28:412-419. 10. Bergman RN 1989 Toward physiological understanding of glucose tolerance.Minimalmodel approach.Lilly lecture.Diabetes 38:1512-1527 11. Stumvoll M,Tataranni A,Stefan N,Vozarova B,Bogardus C 2003 Glucose allostasis.Diabetes 52:903-909 12. Boden G,Shulman GI 2002 Free fatty acids in obesity and type 2 diabetes :defining their role in the development of insulin resistance and β-cell dysfunction. Eur J Clin Invest 32:14-23 13. Pratley RE,Weyer C 2001. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus.Review Diabetologia 44:929-945
2 14. Weyer C,Bogardus C,Mott DM,Pratley RE 1999 The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus J Clin Invest 104:787-794 15, Gerich JE 2003 Contributions of insulin resistance and insulin-secretory defects to the pathogenesis of Type 2 diabetes mellitus. Mayo Clin Proc 78:447-456 16.Elbein SC,Hasstedt SJ,Wegner K,Kahn SE 1999 Heritability of pancreatic β-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab 84:1398-1403 17.Elbein SC,Wegner K,Kahn SE 2000 Reduced β-cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds Diabetes Care 23:221-227 18. Wajchenberg BL 2000 Subcutaneous and visceral adipose tissue :Their relation to the metabolic syndrome Endocr Rev 21:697-738 19 Gerich JE 1998 The genetic basis of type 2 diabetes mellitus : impaired insulin secretion versus impaired insulin sensitivity Endocr Rev 19:491-503 . 20.Gerich JE 2000 Clinical perspective.Insulin resistance is not necessarily an essential component of type 2 diabetes.J Clin Endocrinol Metab 85:2113-2115 21. Donath MY,Halban PA 2004. Decreased beta-cell mass in diabetes:significance ,mechanisms and therapeutic implications. Diabetologia 47:581-589 22. Kahn SE 1996 Regulation of β-cell function in vivo:.from health to disease Diabetes Rev 4:372-389 23 .Roder ME,Porte DJ,Schwartz RS,Kahn SE 1998 Disproportionately elevated proinsulin levels reflect the degree of impaired β cell secretory capacity in patients with noninsulindependent diabetes mellitus.J Clin Endocrinol Metab 83:604-608 24. Gerich JE 2002 Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes ? Diabetes 51(Suppl 1):S117-S121 25. Mitrakou A,Kelley D,Mokan M,Veneman T,Pangburn T,Reilly J,Gerich JE 1992 Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance N Engl J Med 326:22-29 26. Bergstrom RW,Wahl PW,Leonetti DL,Fujimoto WY 1990 Association of fasting glucose levels with delayed secretion of insulin after oral glucose in subjects with glucose intolerance.J Clin Endocrinol Metab 71:1447-1453
Page 1 and 2:
Endocrine Reviews. First published
Page 3 and 4:
3 Sitagliptin (MK-0431) Vildaglipti
Page 5 and 6:
5 associated with impairment of bet
Page 7 and 8:
7 kindreds (but not similar obese c
Page 9 and 10:
9 It is well recognized that the re
Page 11 and 12:
11 Opinions diverge regarding the r
Page 13 and 14: 13 time-dependent establishment of
Page 15 and 16: 15 that plasma FFA support between
Page 17 and 18: 17 generation of reactive oxygen sp
Page 19 and 20: 19 D. Islet-cell amyloid The releva
Page 21 and 22: 21 reduced beta-cell mass can lead
Page 23 and 24: 23 Numbering among the factors for
Page 25 and 26: 25 greater recovery of beta-cell fu
Page 27 and 28: 27 These effects could be dissociat
Page 29 and 30: 29 in in vitro studies in rodent an
Page 31 and 32: 31 suppression of TNF-α expression
Page 33 and 34: 33 Zeender et al. (127) were able t
Page 35 and 36: 35 comparison with both placebo and
Page 37 and 38: 37 Diabetes Prevention Program (DPP
Page 39 and 40: 39 with significant improvement in
Page 41 and 42: 41 mediated by inhibition of glucag
Page 43 and 44: 43 with DM2 (81, 180, 170). Its sub
Page 45 and 46: 45 Table 2. Effects of incretin (GL
Page 47 and 48: 47 Three similarly designed 6-month
Page 49 and 50: 49 function:early (first-phase) ins
Page 51 and 52: 51 whereas the sub-acute effect is
Page 53 and 54: 53 Concerning the potential mediato
Page 55 and 56: 55 in 741 patients with DM2, random
Page 57 and 58: 57 cell function was examined in dr
Page 59 and 60: 59 available to enable comparison o
Page 61 and 62: 61 mathematical model. In a similar
Page 63: 63 to an excessive glucose producti
Page 67 and 68: 4 39. Clark A,Wells CA,Buley ID Cru
Page 69 and 70: 6 63. Yaney GC,Corkey BE 2003 Fatty
Page 71 and 72: 8 89. Bell DSH 2004 Management of t
Page 73 and 74: 10 113. Dubois M,Pattou F,Carr-Cont
Page 75 and 76: 12 135. Li J,Tian H,Ren Y,Yu H,Wang
Page 77 and 78: 14 158 Hansen L, Holst JJ 2005 The
Page 79 and 80: 16 183. Farilla L,Hui H,Bertolloto
Page 81 and 82: 18 206. Visboll T,Agerso H,Krarup T
Page 83 and 84: 20 229. Herman GA,Zhao P-L,Dietrich
Page 85: 22 250. Stoffers DA,Kieffer TJ,Huss
show all

1 BETA-CELL FAILURE IN DIABETES AND PRESERVATION BY ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?